PPIDT00171
Drug Information
| Name | Inotuzumab ozogamicin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB05889 |
| Type | biotech |
| Indication | In the US, inotuzumab ozogamicin is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one year and older.[L50542] In Europe, it is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor ALL. Patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).[L938] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
1 mg
|
| Injection, powder, for solution | Intravenous; Parenteral |
1 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
0.25 mg/1mL
|
| Powder, for solution | Intravenous |
0.9 mg / vial
|
| Injection, powder, for solution | — |
1 mg
|
| Powder, for solution | Intravenous |
1 mg
|